Colorectal cancer is the third leading cause of cancer-related deaths in women in the United States and the second leading cause in men. The death rate from colorectal cancer has been dropping in both men and women for several decades, mainly due to colorectal polyps screening and improved treatment over the last few decades.
Targeted therapy drugs for colorectal cancer include anti- vascular endothelial growth factor (VEGF) therapies that stops VEGF from forming new blood vessels and pass nutrients to tumor cells (also known as, anti-angiogenesis therapy). These include monoclonal antibody therapy such as, Bevacizumab (Avastin), Ramucirumab (Cyramza), Ziv-aflibercept (Zaltrap), and Ramucirumab (Cyramza). When combined with chemo, these drugs can often help patients with advanced colon or rectal cancers to live longer. Anti- epidermal growth factor receptor (EGFR) therapies target EGFR protein that often appears in high amounts on the surface of cancer cells and helps them grow. These include: Cetuximab (Erbitux), and Panitumumab (Vectibix). Regorafenib (Stivarga) is a type of targeted therapy known as a kinase inhibitor, used to treat advanced colorectal cancer. It blocks several kinase proteins that either help tumor cells grow or help form new blood vessels to feed the tumor. Blocking these proteins can help stop the growth of cancer cells. Immune checkpoint inhibitors such as Pembrolizumab (Keytruda) targets PD-1, a protein on immune system cells that normally prevents cells from attacking other cells in the body. Some common chemotherapy drugs used for colorectal cancer include: 5-Fluorouracil (5-FU), Capecitabine (Xeloda), Irinotecan (Camptosar), Oxaliplatin (Eloxatin), Trifluridine and tipiracil (Lonsurf). Dabrafenib and trametinib, the first BRAF and MEK inhibitor combination drugs are in clinical trials, and currently the FDA approved combination in patients with advanced mutated melanoma.
The global colorectal cancer drugs market segmentation is based on drug class – vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EPGR) inhibitors, programmed cell death protein 1/PD1 ligand 1 (PD1/PDL1) inhibitors, B-Raf kinase (BRAF) or MEK inhibitors – mitogen-activated protein kinase (MAPK) / extracellular signal-regulated kinase (ERK), tyrosine kinase (TKI) inhibitors, immunomodulators, and chemotherapies.
The global colorectal cancer drugs market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global colorectal cancer drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global colorectal cancer drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global colorectal cancer drugs market and profiled in this report include AB Science, Amgen, Array BioPharma, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Elli Lilly, Genentech (Roche), Hutchison MediPharma, Merck & Co., Mologen, Regeneron, Sanofi, Sumitomo Dainippon, Taiho Pharmaceutical, and Vaccinogen.